|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:alsoKnownAs
|
gptkb:Acomplia
gptkb:Rimonabant
gptkb:Zimulti
|
|
gptkbp:approvedBy
|
gptkb:European_Union
|
|
gptkbp:CASNumber
|
gptkb:168273-06-1
|
|
gptkbp:category
|
gptkb:anorectic
CB1 receptor antagonist
withdrawn drug
|
|
gptkbp:developedBy
|
gptkb:Sanofi-Aventis
|
|
gptkbp:discoveredIn
|
1994
|
|
gptkbp:hasMolecularFormula
|
gptkb:C22H21Cl3N4O
|
|
gptkbp:IUPACName
|
gptkb:5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-yl-1H-pyrazole-3-carboxamide
|
|
gptkbp:legalStatus
|
withdrawn
|
|
gptkbp:mechanismOfAction
|
CB1 receptor antagonist
|
|
gptkbp:molecularWeight
|
463.8 g/mol
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL37539
104850
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:depression
anxiety
suicidal ideation
|
|
gptkbp:target
|
gptkb:cannabinoid_receptor_type_1_(CB1)
|
|
gptkbp:UNII
|
N9YNS0M02X
|
|
gptkbp:usedFor
|
anti-obesity medication
|
|
gptkbp:withdrawn
|
gptkb:European_Union
psychiatric side effects
|
|
gptkbp:bfsParent
|
gptkb:rimonabant
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
SR141716
|